Mouwasat Medical Services Company (4002) Fair Value & Analysis
Healthcare · SA · Market cap 12.3B SAR
Fair value as of: Jul 31, 2026
From 26 valuation models · updated today
Share price −2.4% over the past month.
Price vs Fair Value (12 months)
12‑month range 58.14 SAR – 76.60 SAR · fair‑value band 38.89 SAR – 90.27 SAR · the 62.20 SAR price screens below the 71.44 SAR fair value. As of Jul 31, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Mouwasat Medical Services Company (4002) currently trades at 62.20 SAR, while our model-based Fair Value estimate is 71.44 SAR, implying the stock looks roughly 14.9% undervalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Mouwasat Medical Services Company generated revenue of 3.3B SAR at a net margin of 25.1%. Revenue grew 9.1% year over year. It earns a return on equity of 21.3%. Net debt stands at 492M SAR. Fundamentals as of Jul 31, 2026
Our scenario range runs from 38.89 SAR (bear case) to 90.27 SAR (bull case); at 62.20 SAR, the current price sits within that range. The share trades about 20% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -11% fair-value upside, at 15%, 4002 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Mouwasat Medical Services Company, together with its subsidiaries, engages in the acquisition, management, operation, and maintenance of hospitals, medical centers, drug stores, and pharmacies in the Kingdom of Saudi Arabia.
Full company description
Mouwasat Medical Services Company, together with its subsidiaries, engages in the acquisition, management, operation, and maintenance of hospitals, medical centers, drug stores, and pharmacies in the Kingdom of Saudi Arabia. The company operates a network of hospitals that provides medical services and specialized centers, including eye, obesity, cardiology, diabetic, robotic, fertility, rehabilitation, long term care, stroke, and skincare center. It also provides various services comprising inpatient pharmacy services, TPN and IV medication preparation units, chemotherapy medication preparation, anti-coagulant clinic, and clinical pharmacy services. In addition, the company is involved in construction and operation of hospitals, dispensaries, and special clinics; general construction of non-residential buildings, including schools, hospitals, and hotels; demolition of buildings; purchase, sale, and division of land and real estate; off-plan sales activities; operation of colleges and university institutes; and medical operation of hospitals. Further, it wholesales medical equipment and drugs. Mouwasat Medical Services Company was founded in 1974 and is based in Dammam, the Kingdom of Saudi Arabia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Mouwasat Medical Services Company reported revenue of 3.2B SAR in FY2025 versus 2.1B SAR in FY2021, a compound +10.7%/yr. Reported net income was 822M SAR in FY2025, compounding +9.2%/yr from FY2021.
Is 4002 fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FRE | €36.27 | €22.73 | -37% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.76 SGD | 1.28 SGD | -54% |
| Tenet Healthcare Corporation THC | $162.06 | $282.55 | +74% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
| DaVita Inc DVAI34 | R$1,030 | R$1,096 | +7% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,489 | ₹2,128 | -75% |
| Fresenius Medical Care AG FMSC34 | R$112.00 | R$164.58 | +47% |
| Aier Eye Hospital Group 300015 | ¥8.55 | ¥7.64 | -11% |
Compare Mouwasat Medical Services Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Mouwasat Medical Services Company (4002) overvalued or undervalued?
What is the fair value of 4002?
What is the quality score of 4002?
What is the revenue of Mouwasat Medical Services Company (4002)?
What is the net profit margin of 4002?
Does Mouwasat Medical Services Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Mouwasat Medical Services Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.